Max Healthcare Institute Ltd Q4 FY2024 Concall Summary

Key Takeaways

• 14th straight quarter of growth, but PAT dipped: Network gross revenue grew 15% YoY and operating EBITDA grew 15% YoY, yet PAT fell to Rs. 311 crore from Rs. 320 crore, dragged by a higher tax rate, new-hospital losses, and a fair-value adjustment on contingent consideration.
• Capacity, not demand, is the binding constraint: Occupied bed days rose only ~1% YoY because beds are simply not available; this scarcity is pushing ARPOB up 10% YoY to Rs. 78,100 as lower-acuity cases get postponed in favour of complex, higher-realisation work.
• Two new cities, two new brownfields, one new launch: Max entered Lucknow and Nagpur, adding ~750 beds, and will open its 303-bed Dwarka hospital in early June; the brownfield playbook delivered 40% incremental EBITDA margin on Shalimar Bagh’s 122 new beds within 40 days.
• The balance sheet is being deliberately stretched for growth: Net debt rose to fund the Rs. 993 crore Lucknow acquisition, and management is comfortable taking leverage to 2.5x debt-to-EBITDA, citing a 70% post-Ind-AS EBITDA-to-free-cash-flow conversion rate.
• What to watch next quarter: The Dwarka launch ramp and its initial drag on margins, the pace of Lucknow’s occupancy climb beyond 62%, and any update on the CGHS rate rework that management is hoping for.

Volume, Pricing & the Capacity Ceiling

• IPD volume is stuck in low gear: Occupied bed days grew only ~1% YoY and 3% QoQ because existing hospitals are full; the only volume lever until new brownfield or greenfield beds open is to shift the case mix toward higher-acuity, longer-stay procedures.
• ARPOB is the growth engine for now: ARPOB rose 10% YoY to Rs. 78,100, driven by a rising share of oncology, neurology and cardiac sciences, plus tariff increases that included the institutional segment.
• Institutional payor mix is slowly improving: Excluding the newly added Max Shalimar Bagh, the institutional bed share fell from 29% to 27% and institutional OBDs dropped 6% YoY; management says the turn is more about reducing institutional occupied days than about the percentage itself.
• Bed mix is not fully fungible: Surgical quarters demand ICU beds, medical quarters demand rooms, and some hospitals have more ward beds than single rooms; this structural mismatch means occupancy cannot always be optimised to the theoretical maximum.
• Even 100% institutional beds would be EBITDA-positive: On a unit-level, bed-by-bed basis, institutional patients still contribute positively, so the payor-mix improvement is about margin enhancement, not loss avoidance.

New Capacity: Brownfields, Greenfields & the Preponement

• Shalimar Bagh’s 122-bed brownfield broke even in 10 days: Management chose to open all 122 beds at once and fill them through institutional patients; by day 40 the incremental beds were generating a 40% EBITDA margin because the incremental cost of running them was very low.
• Dwarka (303 beds) launches in early June: Over 280 people including senior doctors have been onboarded; management expects breakeven by the end of FY25 and a positive contribution in FY26.
• Max Smart (Saket) preponed by nine months: By swapping the phasing of Max Smart and Max Vikrant, 375 beds now arrive in Q1 FY26 instead of FY27; the total bed count across the complex is unchanged.
• Gurugram Sector-56 delayed by up to six months: Slab work is in progress but restricted working hours near residential complexes have slowed the pace; Phase I (300 beds) now expected in Q2 FY26.
• Nanavati Phase I (241 beds) on track for Q4 FY25: The hospital structure should be up by mid-July; this adds quality beds in a Mumbai sub-market where no new hospital has been built in 20 years.
• Mohali (155 beds) and Patparganj (250 beds) are progressing: Mohali’s base raft was completed in May and completion is expected by Q1 FY26; Patparganj has received fire and water NOCs and tendering has begun.
• Capacity will be added in tranches, not all at once: Occupancy ramps in stages, so staffing all beds on day one would be wasteful; management will phase openings to match demand.

Soi: "I'll give you the example of the last brownfield we did. We added about 122 beds on a base of 280 beds. That would have broken even in 10 or 15 days. And by the 40th day, the additional beds were generating 40% EBITDA margin."

Lucknow & Nagpur: The New Geography Bets

• Lucknow is a tertiary-care vacuum for a state the size of Europe: Uttar Pradesh has ~24 crore people and only two corporate hospitals, both in Lucknow; management sees the entire state’s tertiary demand flowing to Lucknow because clinicians are unwilling to move to tier-3 cities.
• Occupancy jumped from 54% to 62% in two months just on Max’s presence: The acquired Sahara Hospital is already ramping; management expects Lucknow’s margin to reach network levels by the end of the year, though EBITDA per bed will take longer because ARPOB starts at ~Rs. 47,000.
• Nagpur is a different animal: It is emerging as a transplant hub driven by organ-donation awareness and a centre for mouth cancer from gutka consumption; competition is significantly lower than in Lucknow, and the market is more comparable to Dehradun.
• Both acquisitions are expected to beat the 20–25% pre-tax ROCE target: Management’s standard acquisition hurdle is 20–25% pre-tax ROCE within 4–5 years; for Lucknow and Nagpur, the belief is that this will be achieved far sooner.
• Expansion plans are already underway: Lucknow will add 140 beds and refurbish 250 by December 2024, with a further 50 beds in FY26 and a new 300-bed tower by Q1 FY27; Nagpur will add 25 beds by Q3 FY25 and another 140 beds within 24–30 months.
• A 5.4-acre land parcel on Lucknow’s Shaheed Path has been acquired: Plans for a ~550-bed hospital will be firmed up once the acquired Sahara operations are turned around.

Soi: "The size of UP itself is the size of Europe, and it is an extremely underserved market."

Margins: The Current Drag & the Recovery Path

• Operating EBITDA margin stood at 28.4%: YoY growth was held back by the cost of people hired for Dwarka, GST on variable management fees, and higher provisioning from the build-up of accounts receivable.
• Three specific headwinds compressed PAT: A higher effective tax rate (Rs. 31 crore impact), net loss from new hospitals (Rs. 11 crore), and a fair-value movement on contingent consideration (Rs. 25 crore) that actually reflects improved projected profitability at managed hospitals.
• Dwarka will be a near-term drag, but two other new capacities are already generating profits and free cash flows: The ~500 beds coming from Shalimar Bagh and the acquired hospitals are already contributing positively, which partly offsets the Dwarka startup cost.
• The profitability playbook for the next 12 months: More international patients for a better payor mix, a richer clinical mix (robotics, oncology, higher-end surgeries), an expected CGHS rate rework, and incremental EBITDA from Lucknow and Nagpur.
• International revenue grew 14% YoY but was held back temporarily: Credit-risk actions and visa issues in two markets (including Iraq, where elections disrupted issuance) subdued the quarter; management intends to double down on overseas offices.

Capital Allocation & the M&A Framework

• Leverage headroom is explicit and ample: Management is comfortable going to 2.5x debt-to-EBITDA; with current EBITDA at circa Rs. 2,000 crore, that implies significant debt capacity for further acquisitions.
• Free cash flow conversion runs at 70%: Post-Ind-AS EBITDA, after interest, tax, working-capital changes and routine capex, converts to free cash flow at a 70% rate, a number management calls significantly high.
• M&A target markets are the 19–20 cities where peers have proven viability: Max will enter if it finds the right targets and is confident of performing better than incumbents; the 20–25% pre-tax ROCE hurdle within 4–5 years is the standard screen.
• Goodwill is tested for impairment, not amortised: Intangible assets are written off over the contract period, and the brand is tested for impairment; this is standard Ind-AS treatment, not a discretionary policy choice.

Soi: "We seek 20% to 25% pre-tax ROCE within 4-5 years from acquisition. In both these cases, our belief is that we will be able to hit that number far sooner than that."

Guidance & Commitments

Key Metrics